{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Natural+killer+cell+infusion&page=2",
    "query": {
      "intervention": "Natural killer cell infusion",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Natural+killer+cell+infusion&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T20:33:41.171Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00640796",
      "title": "Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute",
        "Leukemia, Lymphocytic, Acute, T-Cell",
        "Juvenile Myelomonocytic Leukemia Lymphoblastic",
        "T-cell Lymphoblastic Lymphoma",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Haploidentical donor derived natural killer cell infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "CliniMACS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 22,
      "start_date": "2008-09",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2014-04-24",
      "last_synced_at": "2026-09-28T20:33:41.171Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00640796"
    },
    {
      "nct_id": "NCT02727803",
      "title": "Personalized NK Cell Therapy in CBT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Acute Biphenotypic Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Acute Lymphoblastic Leukemia in Remission",
        "Acute Myeloid Leukemia With Myelodysplasia-Related Changes",
        "Acute Myeloid Leukemia With Variant MLL Translocations",
        "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1",
        "Chemotherapy-Related Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "ISS Stage II Plasma Cell Myeloma",
        "ISS Stage III Plasma Cell Myeloma",
        "Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome With Excess Blasts",
        "Myelodysplastic Syndrome With Gene Mutation",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Previously Treated Myelodysplastic Syndrome",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Refractory Acute Lymphoblastic Leukemia",
        "Refractory Adult Acute Lymphoblastic Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Therapy-Related Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Allogeneic Natural Killer Cell Line NK-92",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anti-Thymocyte Globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Umbilical Cord Blood Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "15 Years to 80 Years"
      },
      "enrollment_count": 100,
      "start_date": "2016-05-19",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-28T20:33:41.171Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02727803"
    },
    {
      "nct_id": "NCT00448201",
      "title": "Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2011-01-07",
      "completion_date": "2012-05-23",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-09-28T20:33:41.171Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00448201"
    },
    {
      "nct_id": "NCT02955550",
      "title": "A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "rhIL-2",
          "type": "DRUG"
        },
        {
          "name": "PNK-007",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Celularity Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2017-01-05",
      "completion_date": "2019-06-04",
      "has_results": false,
      "last_update_posted_date": "2020-07-22",
      "last_synced_at": "2026-09-28T20:33:41.171Z",
      "location_count": 7,
      "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Omaha, Nebraska + 4 more",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02955550"
    },
    {
      "nct_id": "NCT05887882",
      "title": "Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pediatric Brain Tumor",
        "Recurrent Pediatric Brain Tumor",
        "Pediatric Neoplasm"
      ],
      "interventions": [
        {
          "name": "Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Implantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging (MRI)",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Sabine Mueller, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "38 Years",
        "sex": "ALL",
        "summary": "1 Year to 38 Years"
      },
      "enrollment_count": 24,
      "start_date": "2024-05-31",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-09-28T20:33:41.171Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05887882"
    },
    {
      "nct_id": "NCT00274846",
      "title": "Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "in vitro treated peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2005-03",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-09-28T20:33:41.171Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00274846"
    },
    {
      "nct_id": "NCT05099549",
      "title": "Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck",
        "Carcinoma, Non-Small-Cell Lung",
        "Colorectal Neoplasms",
        "Advanced Solid Tumor",
        "Refractory Tumor",
        "Metastatic Tumor"
      ],
      "interventions": [
        {
          "name": "AFM24",
          "type": "DRUG"
        },
        {
          "name": "SNK01",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "NKGen Biotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2021-11-03",
      "completion_date": "2023-09-21",
      "has_results": false,
      "last_update_posted_date": "2024-03-01",
      "last_synced_at": "2026-09-28T20:33:41.171Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Santa Monica, California • Chicago, Illinois",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05099549"
    },
    {
      "nct_id": "NCT02259348",
      "title": "Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia (ALL)",
        "Acute Myeloid Leukemia (AML)",
        "Myeloid Sarcoma",
        "Chronic Myelogenous Leukemia (CML)",
        "Juvenile Myelomonocytic Leukemia (JMML)",
        "Myelodysplastic Syndrome (MDS)",
        "Non-Hodgkin Lymphoma (NHL)"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Interleukin-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Natural killer cell therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "T-cell depleted HPC transplant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CD45RA-depleted HPC transplant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-10",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-09-28T20:33:41.171Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02259348"
    },
    {
      "nct_id": "NCT00145626",
      "title": "HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphocytic Leukemia",
        "Myelodysplasia",
        "Chronic Myeloid Leukemia",
        "Histiocytosis"
      ],
      "interventions": [
        {
          "name": "Chemotherapy and antibodies",
          "type": "DRUG"
        },
        {
          "name": "Miltenyi Biotec CliniMACS",
          "type": "DEVICE"
        },
        {
          "name": "Allogeneic stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "Up to 24 Months"
      },
      "enrollment_count": 40,
      "start_date": "2004-05",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2017-06-19",
      "last_synced_at": "2026-09-28T20:33:41.171Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00145626"
    },
    {
      "nct_id": "NCT00536978",
      "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "ARA-C",
          "type": "DRUG"
        },
        {
          "name": "BCNU",
          "type": "DRUG"
        },
        {
          "name": "Campath-1H",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Stem Cell Transplantation",
          "type": "OTHER"
        },
        {
          "name": "Total body radiation (TBI)",
          "type": "RADIATION"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Adback NK or T Cell",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 22,
      "start_date": "2007-09",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2020-09-24",
      "last_synced_at": "2026-09-28T20:33:41.171Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00536978"
    }
  ]
}